Literature DB >> 28201649

A CK2-RNF4 interplay coordinates non-canonical SUMOylation and degradation of nuclear receptor FXR.

Stéphanie Bilodeau1,2, Véronique Caron1, Jonathan Gagnon1,2, Alexandre Kuftedjian1,2, André Tremblay1,2,3.   

Abstract

Farnesoid X receptor (FXR) is a ligand-activated nuclear receptor that plays a central role in regulating genes involved in bile acid homeostasis, and fat and glucose metabolism. Here, we demonstrate a post-translational interplay between FXR phosphorylation, SUMOylation, and ubiquitination that directs the receptor into an activation-degradation pathway in hepatocytes. We identify a non-canonical SUMOylation motif termed pSuM that conjugates SUMO2 at Lys-325 of FXR under the direct control of casein kinase 2 (CK2), which provides the required negative charge for Ubc9 and PIAS1 to perform SUMOylation, by phosphorylating Ser-327. Lys-325 SUMOylation is indispensable to the promotion of efficient ligand activation and transcriptional coactivation of FXR. Constitutive pSuM activation using a phospho-mimic Ser-327 mutant or catalytic CK2 expression strongly induces SUMO2 conjugation, which directs FXR ubiquitination and proteasome-dependent degradation. We also determine that such SUMOylation-dependent ubiquitination of FXR is mediated by the E3 ubiquitin ligase RNF4, which is required to achieve maximal induction of FXR and optimal up- or downregulation of responsive genes involved in bile acid homeostasis and liver regeneration. Our findings identify a highly regulated atypical SUMO conjugation motif that serves to coordinate FXR transcriptional competence, thereby expanding the intricate dynamics of the SUMOylation process used by incoming signals to govern metabolic gene regulation.
© The Author (2017). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, IBCB, SIBS, CAS. All rights reserved.

Entities:  

Keywords:  26S proteasome; SUMOylation; bile acid; farnesoid receptor; ubiquitination

Mesh:

Substances:

Year:  2017        PMID: 28201649      PMCID: PMC5907841          DOI: 10.1093/jmcb/mjx009

Source DB:  PubMed          Journal:  J Mol Cell Biol        ISSN: 1759-4685            Impact factor:   6.216


  50 in total

1.  SUMO-1 conjugation in vivo requires both a consensus modification motif and nuclear targeting.

Authors:  M S Rodriguez; C Dargemont; R T Hay
Journal:  J Biol Chem       Date:  2000-12-21       Impact factor: 5.157

2.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

Review 3.  Emerging roles of the ubiquitin proteasome system in nuclear hormone receptor signaling.

Authors:  David M Lonard; Bert W O'Malley
Journal:  Prog Mol Biol Transl Sci       Date:  2009-10-07       Impact factor: 3.622

Review 4.  Nuclear hormone receptors: Roles of xenobiotic detoxification and sterol homeostasis in healthy aging.

Authors:  Julia Marianne Hoffmann; Linda Partridge
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-09-18       Impact factor: 8.250

Review 5.  Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

Authors:  James S Duncan; David W Litchfield
Journal:  Biochim Biophys Acta       Date:  2007-08-30

6.  Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation.

Authors:  Che-Chang Chang; Mandar T Naik; Yen-Sung Huang; Jen-Chong Jeng; Pei-Hsin Liao; Hong-Yi Kuo; Chun-Chen Ho; Yung-Lin Hsieh; Chiou-Hong Lin; Nai-Jia Huang; Nandita M Naik; Camy C-H Kung; Shu-Yu Lin; Ruey-Hwa Chen; Kun-Sang Chang; Tai-Huang Huang; Hsiu-Ming Shih
Journal:  Mol Cell       Date:  2011-04-08       Impact factor: 17.970

Review 7.  Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms.

Authors:  Danielle A A Hollman; Alexandra Milona; Karel J van Erpecum; Saskia W C van Mil
Journal:  Biochim Biophys Acta       Date:  2012-07-20

8.  Coordinate regulation of estrogen receptor β degradation by Mdm2 and CREB-binding protein in response to growth signals.

Authors:  M Sanchez; N Picard; K Sauvé; A Tremblay
Journal:  Oncogene       Date:  2012-02-20       Impact factor: 9.867

Review 9.  Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR.

Authors:  Anna C Calkin; Peter Tontonoz
Journal:  Nat Rev Mol Cell Biol       Date:  2012-03-14       Impact factor: 94.444

10.  Phosphorylation-dependent sumoylation regulates estrogen-related receptor-alpha and -gamma transcriptional activity through a synergy control motif.

Authors:  Annie M Tremblay; Brian J Wilson; Xiang-Jiao Yang; Vincent Giguère
Journal:  Mol Endocrinol       Date:  2007-12-06
View more
  6 in total

1.  Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications.

Authors:  Carl C Ward; Jordan I Kleinman; Scott M Brittain; Patrick S Lee; Clive Yik Sham Chung; Kenneth Kim; Yana Petri; Jason R Thomas; John A Tallarico; Jeffrey M McKenna; Markus Schirle; Daniel K Nomura
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

2.  SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis.

Authors:  Jiyu Zhou; Shuang Cui; Qingxian He; Yitong Guo; Xiaojie Pan; Pengfei Zhang; Ningning Huang; Chaoliang Ge; Guangji Wang; Frank J Gonzalez; Hong Wang; Haiping Hao
Journal:  Nat Commun       Date:  2020-01-13       Impact factor: 14.919

Review 3.  Targeting Farnesoid X receptor (FXR) for developing novel therapeutics against cancer.

Authors:  Sosmitha Girisa; Sahu Henamayee; Dey Parama; Varsha Rana; Uma Dutta; Ajaikumar B Kunnumakkara
Journal:  Mol Biomed       Date:  2021-07-10

4.  Redox-sensitive activation of CCL7 by BRG1 in hepatocytes during liver injury.

Authors:  Ming Kong; Wenhui Dong; Yuwen Zhu; Zhiwen Fan; Xiulian Miao; Yan Guo; Chengping Li; Yunfei Duan; Yunjie Lu; Zilong Li; Yong Xu
Journal:  Redox Biol       Date:  2021-07-24       Impact factor: 11.799

Review 5.  Post-Translational Modifications of FXR; Implications for Cholestasis and Obesity-Related Disorders.

Authors:  Monique D Appelman; Suzanne W van der Veen; Saskia W C van Mil
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-27       Impact factor: 5.555

Review 6.  Posttranslational control of lipogenesis in the tumor microenvironment.

Authors:  Yahui Zhu; Xingrong Lin; Xiaojun Zhou; Edward V Prochownik; Fubing Wang; Youjun Li
Journal:  J Hematol Oncol       Date:  2022-08-29       Impact factor: 23.168

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.